DRIO 241220 5.00C (DRIO241220C5000) Stock Options, News & Quotes

0.03
0.000.00%

15min DelayClose Dec 4 16:00 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Nov 21 07:34

NEWS

$DarioHealth (DRIO.US)$
Dario Signs Four New Employer Contracts Across Full Product Suite
DarioHealth (Nasdaq: DRIO) has secured four new self-insured employer contracts, expected to go live in Q1 2025. These contracts cover Dario's complete platform suite, with clients opting for multi-condition offerings rather than single-condition solutions. The company projects to achieve approximately 25 new client signings in 2024, representing a 35% growth in client base compared to 2023.
These new ...

Jaguar8

Sep 10 07:32

NEWS

$DarioHealth (DRIO.US)$
Dario Publishes New Research Revealing How Physical Activity Mediates the Impact of Depression on Blood Glucose Levels in Individuals with Diabetes or Prediabetes
DarioHealth Corp. (Nasdaq: DRIO) has published a new study in Frontiers in Endocrinology, demonstrating the effectiveness of its cardiometabolic solution for individuals with diabetes or prediabetes and depression. The research, involving 989 users over 12 months, reveals:
Members with depression showed highe...

NRAO

Sep 3 10:37

$DarioHealth (DRIO.US)$ holding this for almost 4 months

Trytosaveabit

Jul 16 07:32

Update

$DarioHealth (DRIO.US)$ Reuters· just
DarioHealth-New Contract With National Employer to Provide Cardiometabolic Solution With Integrated Support for Glp-1S to Employees Beginning in Q3

Jaguar8

Jun 25 07:30

NEWS

$DarioHealth (DRIO.US)$
Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1
New research presented by DarioHealth at the 84th Annual ADA Scientific Sessions demonstrates the efficacy of their digital health platform in sustaining behavior change for members taking GLP-1 medications. Data over a 12-month period show significant improvements in healthy lifestyle tracking and blood glucose control. Notably, 31% of Type 2 diabetes members achieved results ...